<DOC>
	<DOCNO>NCT01462357</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety Cervarix administer accord 2-dose schedule 0 , 6 month compare Gardasil , administer accord 2-dose schedule 0 , 6 month standard 3-dose schedule 0 , 2 , 6 month 9-14 year old healthy female .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline Biologicals ' Human Papillomavirus ( HPV ) Vaccine ( GSK-580299 ) Merck 's GardasilÂ® Vaccine When Administered According Alternative 2-dose Schedules 9-14 Year Old Females</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol subject investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR [ ] ) comply requirement protocol . A female , include , 9 14 year age time first vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject prior enrolment study . In addition , capable , subject sign personally date write informed assent . Healthy subject establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period two month completion vaccination series . Pregnant breastfeeding . A woman plan become pregnant , likely become pregnant ( determined investigator ) planning discontinue contraceptive precaution vaccination phase study , i.e . two month last vaccine dose . Previous vaccination HPV plan administration another HPV vaccine study foreseen protocol . Child care . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period ( Month 36 ) . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . History allergic disease , suspect allergy reaction likely exacerbate component study vaccine . Cancer autoimmune disease treatment . Planned administration/administration vaccine foreseen study protocol within 30 day dose vaccine . Administration routine meningococcal , hepatitis B , hepatitis A , inactivated influenza , diphtheria/tetanus and/or diphtheria/tetanuscontaining vaccine 8 day dose study vaccine allow . Enrolment defer subject outside specify window . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Previous administration vaccine component . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screening test , opinion investigator precludes administration study vaccine . Acute disease and/or fever time enrolment . Drug and/or alcohol abuse .</criteria>
	<gender>Female</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Human papillomavirus</keyword>
	<keyword>Safety</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>Immune response</keyword>
</DOC>